Chemoprophylaxis by Interferons or Inducers against Chemical Carcinogenesis

  • Ernest C. Borden
  • Younan A. Sidky
  • George T. Bryan


Human malignancies arise commonly after exposure to environmental carcinogens. Bladder cancer is a well-studied and excellent preclinical model for this process. Transitional cell carcinoma (TCC) of the lower urinary tract accounts for approximately 4% of human cancers. Most of the TCC arise in the urinary bladder, with a male:female ratio in the U.S. of about 3:1. Chemical carcinogen-induced mouse and rat tumors in situ and transplantable bladder cancer models, which mimic the pathogenesis of the human disease, have been developed (1–4). Neoplasms can be histologically graded and staged in a manner similar to that for human bladder carcinoma.


Bladder Cancer Transitional Cell Carcinoma Chemical Carcinogenesis Urinary Bladder Cancer Bladder Transitional Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    E. Ertürk, J.M. Price, J.E. Morris, S.M. Cohen, R.S. Leith, A.M. VonEsch, and A.J. Crovetti, The production of carcinoma of the urinary bladder in rats by feeding N-[4-(5-nitro-2-furyl)-2-thiazolyljformamide. Cancer Res. 27: 1998–2002 (1967).PubMedGoogle Scholar
  2. 2.
    E. Ertürk, S.M. Cohen, J.M. Price, and G.T. Bryan, Pathogenesis, histology and transplantability of urinary bladder carcinomas induced by albino rats by oral administration of N-[4-(5-nitro-2-furyl)-2-thiazolyljformamide. Cancer Res. 29: 2219–2228 (1969).PubMedGoogle Scholar
  3. 3.
    E. Ertürk, S.M. Cohen, and G.T. Bryan, Urinary bladder carcinogenicity of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide in female Swiss mice. Cancer Res. 30: 1309–1311 (1970).PubMedGoogle Scholar
  4. 4.
    S.M. Cohen, G.M. Lower, Jr., E. Ertürk, and G.T. Bryan, Comparative carcinogenicity in Swiss mice of N-[4-(5-nitro-2-furyl)-2-thiazolyl]-acetamide and structurally related 5-nitrofurans and 4-nitrobenzenes. Cancer Res. 33: 1593–1597 (1973).PubMedGoogle Scholar
  5. 5.
    G. T. Bryan, The pathogenesis of experimental bladder cancer. Cancer Res. 37–2813-2816 (1977).PubMedGoogle Scholar
  6. 6.
    J.B. Jacobs, M. Arai, S.M. Cohen, and G.H. Friedell, A long-term study of reversible and progressive urinary bladder cancer lesions in rats fed N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide. Cancer Res. 37: 2817–2821 (1977).PubMedGoogle Scholar
  7. 7.
    M.S. Soloway, Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res. 37: 2918–2929 (1977).PubMedGoogle Scholar
  8. 8.
    M.S. Soloway and W.M. Murphy, Experimental chemotherapy of bladder cancer — Systemic and intravesical. Seminars Oncol. 6: 166–183 (1979).Google Scholar
  9. 9.
    A. Yagoda, Phase II trials with cis-dichlorodiammineplatinum (II) in the treatment of urothelial cancer. Cancer Treat. Rep. 63: 1565–1572 (1979).PubMedGoogle Scholar
  10. 10.
    W.H. Harker, F.S. Freiha, L.D. Shortliffe, F.J. Meyers, J.F. Hannigan, Jr., M.S. Flam, and F.M. Torti, Cisplatin, methotrexate and vinblastine (CMV) chemotherapy for metastatic transitional cell carcinoma of the urinary tract (TCC): evaluation of complete response by site. Proc. Amer. Assoc. Clin. Oncol. 3: 160 (1984).Google Scholar
  11. 11.
    R. Hahn, L. Kvols, S. Frytak, and W. Nichols, Phase II trial of combination VP 16 and cis-platinum in advanced measurable bladder cancer. Proc. Amer. Assoc. Clin. Oncol. 3: 162 (1984).Google Scholar
  12. 12.
    E.C. Borden, Y.A. Sidky, D.S. Groveman, and G.T. Bryan, Antitumor effects of polyribonucleotides for mouse transitional cell carcinoma enhanced by cyclophosphamide. Cancer Res. 45–50, 1985.Google Scholar
  13. 13.
    Y.A. Sidky, E.C. Borden, W. Wierenga, and G.T. Bryan, Inhibitory effects of interferon-inducing pyrimidinones on the growth of transplantable mouse bladder tumors. Cancer Res. 46: 3798–3802, (1986).PubMedGoogle Scholar
  14. 14.
    E.C. Borden, N. Yamamoto, T.F. Hogan, B.S. Edwards, and G.T. Bryan, Interferons: preclinical rationale for trials in human bladder carcinoma. In Interferon. Properties, Mode of Action, Production, Clinical Application. Proc. 3rd Intern. Expert Meeting of the Deutsche Stiftung für Krebsforschung, 1982 (K. Münk and H. Kirchner, Eds.) pp. 42–52. S. Karger-Verlag, Basel.Google Scholar
  15. 15.
    E.C. Borden, D.S. Groveman, T. Nasu, C. Reznikoff, and G.T. Bryan, Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro. J. Urol. 132: 800–803 (1984).PubMedGoogle Scholar
  16. 16.
    D.S. Groveman, E.C. Borden, J.A. Merritt, H.I. Robins, R. Steeves, and G.T. Bryan, Augmented antiproliferative effects of interferons at elevated temperatures against human bladder carcinoma cell lines. Cancer Res. 44: 5517–5521 (1984).PubMedGoogle Scholar
  17. 17.
    F.M. Torti, L.D. Shortliffe, R.D. Williams, J.T. Spaulding, J.F. Hannigan, Jr., J. Palmer, F.J. Meyers, M. Higgins, and F.S. Freiha, Superficial bladder cancers are responsive to alpha2 interferon administered intravesically. Proc. Amer. See. Clin. Oncol. 3: 160 (1984).Google Scholar
  18. 18.
    E.C. Borden, Interferons: rationale for clinical trials in neoplastic disease. Ann. Int. Med. 91: 472–479 (1979).PubMedGoogle Scholar
  19. 19.
    M. Krim, Towards tumor therapy with interferons. Part I. Interferons: production and properties. Blood. 55: 711–721 (1980).PubMedGoogle Scholar
  20. 20.
    M. Krim, Towards tumor therapy with interferons. Part II. Interferons: in vivo effects. Blood. 55: 875–884 (1980).PubMedGoogle Scholar
  21. 21.
    E.C. Borden, Interferons and cancer: How the promise is being kept. In: Interferons, Vol. 5, 1984 (I. Gresser, Ed.) pp. 43–83. Academic Press, London.Google Scholar
  22. 22.
    E.C. Borden, Progress toward therapeutic application of interferons, 1979–1983. Cancer. 54: 2770–2776 (1984).PubMedCrossRefGoogle Scholar
  23. 23.
    P.E. Came and D.H. Moore, Effect of exogenous interferon treatment on mouse mammary tumors. J. Natl. Cancer Inst. 48: 1151–1154 (1972).PubMedGoogle Scholar
  24. 24.
    J.K. Ball and J.A. McCarter, Effect of polyinosinic-polycytidylic acid on induction of primary or transplanted tumors by chemical carcinogen or irradiation. J. Natl. Cancer Inst. 46: 1009–1014 (1971).PubMedGoogle Scholar
  25. 25.
    F. Lacour, G. Delage, and C. Chianale, Reduced incidence of spontaneous mammary tumors in C3H/He mice after treatment with polyadenylate-polyuridylate. Science 187: 256–257 (1975).PubMedCrossRefGoogle Scholar
  26. 26.
    R.A. Salerno, C.E. Whitmire, I.M. Garcia, and R.J. Huebner, Chemical carcinogenesis in mice inhibited by interferon. Nature (London) New Biol. 239: 31–32 (1972).Google Scholar
  27. 27.
    K. Elgjo and M. Degré, Polyinosinic-polycytidylic acid in two-stage skin carcinogenesis. Effect on epidermal growth parameters and interferon induction in treated mice. J. Natl. Cancer Inst. 51: 171–177 (1973).Google Scholar
  28. 28.
    I. Gresser, F. Belardelli, C. Maury, M.T. Maunoury, and M.G. Tovey, Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors. J. Exp. Med. 158: 2095–2107 (1983).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • Ernest C. Borden
    • 1
  • Younan A. Sidky
    • 1
  • George T. Bryan
    • 1
  1. 1.Department of Human OncologyUniversity of Wisconsin Clinical Cancer CenterMadisonUSA

Personalised recommendations